Physician profile
Lee Jones
NPI 1639532468
$7,624.47
in general payments reported to CMS, 2019-2025
21 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $554 · 2021: $1,011 · 2022: $1,347 · 2023: $1,273 · 2024: $1,318 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,415.73 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Mallinckrodt Hospital Products INC. | $1,445.89 | 2020-2025 | Acthar |
| Abbvie INC. | $838.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $514.51 | 2020-2023 | |
| Oyster Point Pharma, INC. | $459.14 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $391.11 | 2020-2024 | Cequa |
| Allergan, INC. | $389.83 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $330.37 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $281.46 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Glaukos Corporation | $149.36 | 2022-2025 | Idosetr |
| Ivantis, INC | $104.79 | 2020 | |
| Biotissue Holdings INC. | $98.93 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $36.98 | 2025 | |
| Rxsight INC | $35.58 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $24.70 | 2020-2023 | Tecnis Iol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.43 | 2021 | |
| Aerie Pharmaceuticals, INC. | $21.00 | 2021 | |
| Ocular Therapeutix, INC. | $18.34 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.44 | 2022 | |
| Amgen INC. | $14.62 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.